NEET-PG 2019 - Obstetrics and Gynecology PYQs Practice Questions

Q: Nuchal translucency in USG can be detected at_____weeks of gestation.

11-13 weeks. ***11-13 weeks*** - Nuchal translucency (NT) is a **first-trimester ultrasound marker** used for screening for chromosomal abnormalities like **Down syndrome**. - The optimal window for accurate measurement is between **11 weeks 0 days and 13 weeks 6 days** of gestation, or when the crown-rump length (CRL) is between 45 mm and 84 mm. *18-20 weeks* - This period is typically dedicated to the **anomaly scan** or **mid-pregnancy scan**, which focuses on detecting structural abnormalities in the fetus. - While other markers like **nuchal fold thickness** can be assessed later, the diagnostic value of Nuchal Translucency is decreased by this time. *8-10 weeks* - At this early stage, the fetus is generally **too small** for accurate and consistent measurement of the nuchal translucency. - The nuchal translucency itself might not be fully developed or easily distinguishable for precise measurement. *20-22 weeks* - By this gestational age, the **nuchal translucency has usually resolved** or is no longer a reliable marker for chromosomal screening. - This period is well beyond the recommended window for NT measurement, making it unsuitable for this specific screening test. [Practice more Obstetrics and Gynecology PYQs on OnCourse]

Q: What is the presenting diameter of a fully flexed head?

Suboccipito-bregmatic diameter. ***Suboccipito-bregmatic diameter*** - This diameter measures from the **nape of the neck** (**suboccipital region**) to the **anterior fontanelle** (**bregma**), which is the smallest presenting diameter of the fetal head when it is in **full flexion**. - A fully flexed head presents the smallest and most favorable diameter for vaginal birth, allowing for optimal passage through the birth canal. *Suboccipito-frontal diameter* - This diameter is measured from the **nape of the neck to the center of the forehead**, indicating a less flexed head than the suboccipito-bregmatic diameter. - While it represents some flexion, it is not the ideal presenting diameter for a fully flexed head and is larger than the suboccipito-bregmatic diameter. *Occipito-frontal diameter* - This diameter is measured from the **occipital protuberance to the forehead**, representing a **deflexed** or **partially flexed** head. - This presentation is less favorable for vaginal delivery as it is a larger diameter than either the suboccipito-bregmatic or suboccipito-frontal diameters. *Biparietal diameter* - This diameter measures the **widest transverse diameter of the fetal head**, between the two parietal eminences. - While clinically important for assessing head size and growth, it is **not a presenting longitudinal diameter** that describes the leading part of the fetal head during engagement and descent. [Practice more Obstetrics and Gynecology PYQs on OnCourse]

Q: The major contributor to amniotic fluid after 20 weeks of gestation is:

Fetal urine. ***Fetal urine*** - After **20 weeks of gestation**, the **fetal kidneys** are fully functional, and fetal urination becomes the primary source of amniotic fluid. - This contribution is crucial for the **volume of amniotic fluid** and plays a vital role in **fetal lung development** by allowing the fetus to "breathe" the fluid. *Ultrafiltrate of maternal plasma* - While an ultrafiltrate of maternal plasma contributes to the early amniotic fluid volume, its significance diminishes as the **fetal kidneys mature** past 20 weeks. - This source primarily provides water and dissolved solutes, but not a substantial volume. *Fluid from fetal lungs* - Fluid produced by the fetal lungs also contributes to amniotic fluid, but its volume is considerably smaller than that from **fetal urine**, especially after 20 weeks. - It mainly includes pulmonary surfactants and other specific proteins important for lung maturation. *Fetal skin* - Before **keratinization** of the fetal skin (around 20-22 weeks), the skin is permeable and allows for transepidermal fluid transport, contributing to amniotic fluid. - However, once **keratinization** is complete, the skin becomes impermeable, and its contribution to amniotic fluid becomes negligible. [Practice more Obstetrics and Gynecology PYQs on OnCourse]

Q: A patient with recurrent abortion is diagnosed to have antiphospholipid syndrome. What will be the treatment?

Aspirin and Low molecular weight Heparin. ***Aspirin and Low molecular weight Heparin*** - The combination of **low-dose aspirin (75-100 mg daily)** and **low molecular weight heparin (LMWH)** is the **standard of care** for pregnant women with antiphospholipid syndrome (APS) to prevent recurrent pregnancy loss. - **Aspirin** inhibits platelet aggregation and reduces thrombosis, while **LMWH** provides anticoagulation to prevent placental thrombosis and improve pregnancy outcomes. - This combination has been shown to **increase live birth rates** from approximately 40% (untreated) to **70-80%** in women with APS. *Aspirin alone* - While aspirin is part of the treatment regimen, **aspirin monotherapy is insufficient** for preventing recurrent pregnancy loss in patients with established APS. - Randomized controlled trials have demonstrated that adding heparin to aspirin **significantly improves live birth rates** compared to aspirin alone. *Aspirin, Low molecular weight Heparin, and Prednisolone* - **Corticosteroids (prednisolone)** are **not recommended** as routine treatment for recurrent pregnancy loss in APS patients due to potential maternal complications (gestational diabetes, hypertension, infection) and fetal risks. - Corticosteroids might be considered only in specific cases with coexisting autoimmune conditions (e.g., SLE), but they are **not first-line therapy** for APS-related pregnancy loss. *No treatment required* - **Antiphospholipid syndrome (APS)** is a significant cause of recurrent pregnancy loss due to placental thrombosis and impaired placental function. - **Untreated APS** carries a **high risk** (>70%) of pregnancy loss, along with increased risks of fetal growth restriction, preeclampsia, and preterm delivery, making treatment **essential** for a successful pregnancy outcome. [Practice more Obstetrics and Gynecology PYQs on OnCourse]

Q: Which of the following treatments is used for vulvar atrophy and itching?

Estrogen ointment. ***Estrogen ointment*** * **Estrogen ointment** is the primary treatment for vulvar atrophy and itching because it directly addresses the underlying cause of these symptoms, which is the decline in estrogen levels after **menopause**. * By restoring estrogen to the vulvar tissues, it helps to **thicken the epithelium**, improve blood flow, and increase lubrication, thereby alleviating dryness, itching, and discomfort. *Antihistamines* * **Antihistamines** are used to treat allergic reactions and reduce itching associated with conditions like hives or insect bites, but they do not address the hormonal deficiency causing vulvar atrophy. * While they might temporarily relieve some itching, they do not treat the underlying **tissue thinning** and dryness characteristic of vulvar atrophy. *Tamoxifen* * **Tamoxifen** is a selective estrogen receptor modulator (SERM) primarily used in the treatment and prevention of breast cancer, as it blocks estrogen's effects in breast tissue. * However, in vulvovaginal tissues, **tamoxifen can actually worsen atrophy and dryness** due to its anti-estrogenic effects, making it an inappropriate treatment for vulvar atrophy. *None of the options* * This option is incorrect because **estrogen ointment** is a well-established and effective treatment specifically designed to address vulvar atrophy and associated itching, by restoring estrogen levels to the affected tissues. [Practice more Obstetrics and Gynecology PYQs on OnCourse]

Question 1

Nuchal translucency in USG can be detected at_____weeks of gestation.

Accepted Answer

11-13 weeks

Answer

18-20 weeks

Answer

8-10 weeks

Answer

20-22 weeks

Question 2

What is the presenting diameter of a fully flexed head?

Accepted Answer

Suboccipito-bregmatic diameter

Answer

Suboccipito-frontal diameter

Answer

Occipito-frontal diameter

Answer

Biparietal diameter

Question 3

The major contributor to amniotic fluid after 20 weeks of gestation is:

Accepted Answer

Fetal urine

Answer

Fetal skin

Answer

Ultrafiltrate of maternal plasma

Answer

Fluid from fetal lungs

Question 4

A patient with recurrent abortion is diagnosed to have antiphospholipid syndrome. What will be the treatment?

Accepted Answer

Aspirin and Low molecular weight Heparin

Answer

Aspirin alone

Answer

Aspirin, Low molecular weight Heparin, and Prednisolone

Answer

No treatment required

Question 5

Which of the following treatments is used for vulvar atrophy and itching?

Accepted Answer

Estrogen ointment

Answer

Antihistamines

Answer

Tamoxifen

Answer

None of the options

Question 6

Which of the following statement is correct about acute fatty liver of pregnancy?

Accepted Answer

Mostly seen in last trimester

Answer

May be associated with decreased uric acid

Answer

Occurs in 1 in 1000 pregnancies

Answer

Not related to the gender of the fetus

Question 7

A 60-year-old woman comes with 3rd degree uterine prolapse. What will be the management?

Accepted Answer

Vaginal hysterectomy with pelvic floor repair

Answer

Pelvic floor repair

Answer

Sacrospinous fixation

Answer

Pessary

Question 8

PGF2 alpha maximum dose in PPH is-

Accepted Answer

2 mg

Answer

200 µg

Answer

20 mg

Answer

1000 µg

Question 9

Chromosome number of partial hydatidiform mole is-

Accepted Answer

69 chromosomes

Answer

46 XX

Answer

45 XO

Answer

47 chromosomes (XXY)

Question 10

Female with 41 wk gestation confirmed by radiological investigation, very sure of her LMP, no uterine contractions, no effacement and no dilatation. What should be done to induce labor?

Accepted Answer

PGE1 tab

Answer

PGE2 gel

Answer

PGF2alpha

Answer

Intracervical foley’s

NEET-PG 2019 — Obstetrics and Gynecology